Chad Coberly, CEO of Tetra Therapeutics, a Shionogi Group Company, presented about BPN14770, a PDE4 inhibitor, during the Industry Updates keynote session at the 18th International Fragile X Conference. BPN14770 is in Phase 2b/3 trials in Fragile X syndrome with the goal of becoming an FDA-approved treatment for cognition in FXS. Tetra is now enrolling participants in their BPN14770 trial. More information about the trials can be found here.
Chad spoke about the status of Tetra’s Fragile X program, including their Phase 2 trial results, their current Phase 2b/3 BPN14770 trials, and their hopeful timeline for approval. Learn more about Tetra and their BPN14770 trials by watching their 2022 Industry Updates presentation or vising their MyFXResearch post.